Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Seeks US FDA Rationale For Rx Drug Advertising Studies

Executive Summary

Trade association says research projects are often unnecessary, questions studies of low-internet users and how disclosures about a product affect viewer perceptions.

You may also be interested in...



Over PhRMA’s Objections, US FDA To Study Accelerated Approval Disclosures in DTC Ads

PhRMA argued the study is duplicative of previous project and lacks practical utility. Agency says it is replicating the prior study in a new patient population and testing additional versions of accelerated approval disclosure. Agency makes minor revisions to the study questionnaire.

PhRMA Criticizes 'Exponential Pace' Of FDA Rx Drug Advertising Studies

US FDA responds to comments on proposed study of product disclosures and study of amount and location of risk information.

Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information

Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel